今日，市值748.8亿美元、毛利率高达71.81%的制药巨头GSK plc（LSE/NYSE: GSK）宣布完成对波士顿生物制药公司IDRx, Inc.的收购。此项交易总额可达11.5亿美元，包括10亿美元的首付款和潜在的里程碑付款。根据 InvestingPro 数据显示，GSK保持着强劲的财务健康状况，为战略收购奠定了良好基础。

葛兰素史克公司 (LSE/NYSE: GSK) 宣布，美国食品药品监督管理局 (FDA) 已批准 PENMENVY（脑膜炎球菌 A、B、C、W 和 Y 组疫苗）供 10 至 25 岁人群使用。该疫苗针对通常导致侵袭性脑膜炎球菌病 (IMD) ...

▎药明康德内容团队编辑GSK日前宣布，美国FDA已批准其组合疫苗Penmenvy（MenABCWY）上市，在10~25岁人群中使用。这款疫苗针对脑膜炎球菌中最常见的5大血清群，它们通常是导致侵袭性脑膜炎球菌病（IMD）的原因。此前，该疗法入选了业内知 ...

市值740亿美元的全球制药巨头GSK plc（LSE/NYSE: GSK）今日宣布，将任命牛津大学医学科学部主任Gavin Screaton博士为公司独立非执行董事，任期自2025年5月1日起生效。Screaton博士将接替服务九年后退休的Jesse ...

GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for ...

The studies confirmed that the vaccine has a safety profile consistent with the licensed meningococcal vaccines of GSK. The ...

(HealthDay News) — The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active immunization against invasive meningococcal disease (IMD), ...

The story has been updated to correct the FDA approval date to Friday, February 14 On Friday, February 14, the FDA approved ...

你知道脑膜炎球菌病的潜在威胁吗？这一罕见却严重的疾病每年导致数以万计的感染病例，尤其在10至25岁的人群中，感染风险更高。最近，GSK宣布其组合疫苗Penmenvy（MenABCWY）获得美国FDA批准，这无疑是在防控脑膜炎球菌病道路上的一次重要突破。

UK pharma major GSK late Friday announced that the US Food and Drug Administration (FDA) has approved Penmenvy (meningococcal ...

GSK (GSK) plc announced that the Food and Drug Administration has approved Penmenvy for use in individuals aged 10 through 25 years. The ...

Tony Wood, Chief Scientific Officer, GSK, said: "We are excited about the opportunities ahead to help improve meningococcal vaccination coverage in the United States, especially for IMD caused by ...